Related Experiment Video

Updated: May 17, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Metabolism of kidney cancer: from the lab to clinical practice

Sunil Sudarshan1, Jose A Karam, James Brugarolas

  • 1Department of Urology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. sudarshan@uab.edu

European Urology
|October 16, 2012
PubMed
Abstract

Insights

Altered metabolism drives renal cancer development. Understanding these metabolic changes, particularly those linked to von Hippel-Lindau (VHL) loss and hypoxia-inducible factor (HIF), is key to new treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Metabolic Research

Background:

  • Growing evidence links metabolic alterations to renal cancer pathogenesis.
  • Understanding these metabolic shifts is crucial for comprehending kidney cancer development.

Purpose of the Study:

  • To review the metabolic impacts of genes and signaling pathways frequently involved in renal cancer.
  • To synthesize current knowledge on renal cancer metabolism.

Main Methods:

  • Systematic literature review using PubMed.
  • Search terms included: renal cancer, metabolism, HIF, VHL.

Main Results:

  • Renal cancer metabolism is increasingly understood through translational, in vitro, and in vivo studies.
  • Von Hippel-Lindau (VHL) loss is a key driver, increasing hypoxia-inducible factor (HIF) and promoting a glycolytic phenotype.
  • Metabolic derangements are also observed in other renal cancer subtypes, linked to causative genes.

Conclusions:

  • Genetic insights into renal cancer have significantly advanced our understanding of its metabolism.
  • Further research into the metabolic basis of renal cell carcinoma can inform novel therapies and biomarkers.

More Related Videos

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...